Dr. Dolsten has served as President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President of Pfizer Inc., one of the largest public pharmaceutical companies in the world, since 2010. Prior to joining Wyeth, Dr. Dolsten was a Private Equity Partner at Orbimed Advisors, LLC and Executive Vice President, Head of Pharma Research at Boehringer Ingelheim. ‘Making the consolidation under one leader is a natural and progressive step to take at this point,’ said Jeffrey Kindler, Pfizer’s chairman and chief executive. Dolsten formerly headed r&d at Wyeth and after Pfizer acquired the company he became president of Pfizer’s BioTherapeutics Research & Development division, while Mackay took charge of PharmaTherapeutics Research & Development. Dr. Dolsten has served as a member of our Board of Directors since March 2015. Mikael Dolsten is Chief Scientific Officer at Pfizer, Inc. View Mikael Dolsten’s professional profile on Relationship Science, the database of decision makers. In addition, he makes $9,598,040 as Chief Scientific Officer, President - Worldwide Research a Development and Medical at Pfizer. Dolsten formerly headed r&d at Wyeth and after Pfizer acquired the company he became president of Pfizer’s BioTherapeutics Research & Development division, while Mackay took charge of PharmaTherapeutics Research & Development. He is a member of the Pfizer Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. Semantic Scholar profile for Mikael Dolsten, with 1 highly influential citations and 4 scientific research papers. Dr. Dolsten served as President of Worldwide Research and Development and Senior Vice President of Pfizer from May 2010 until December 2010 and President of Pfizer BioTherapeutics Research & Development Group and Senior Vice President of Pfizer from 2009 until 2010. https://www.lifescienceleader.com/doc/the-story-of-pfizer-s-r-d-turnaround-0001 Form 4 (Reporting) Published: 2019-03-01 19:29:57 Submitted: 2019-03-01 Filing Agent: CT's hCue Period Ending In: 2019-02-27. De acordo com Mikael Dolsten, líder científico da Pfizer, a vacina desenvolvida pela empresa farmacêutica pode estar disponível em outubro “para milhares de pessoas”. Mikael Dolsten has become the sole executive in charge of r&d at Pfizer following the departure of Martin Mackay to AstraZeneca. Mikael Dolsten, M.D., Ph.D. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer Inc. Mikael Dolsten focuses on advancing Pfizer’s scientific breakthrough leadership in small-molecule medicines, biotherapeutics, gene therapies and vaccines. ‘Mikael’s scientific expertise, vision for r&d and commercial mindset have distinguished him at Pfizer and uniquely qualify him to lead our r&d colleagues and advance our pipeline,’ added Kindler. Mikael Dolsten, MD, PhD Director. SEC Form 4 FORM 4: UNITED … Mikael Dolsten is on Facebook. 28-May-2010 . He is a member of the Pfizer Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. Coronavirus Do You Need to Get Tested for COVID-19? JERUSALEM (JTA) – As the American drug company Moderna announced Monday that it had developed a COVID-19 vaccine that is 94.5% effective, Israeli scientist Tal Zaks was among the company leaders touting the good news to the media. Mikael Dolsten is currently associated with one company, according to public records. He was President of Worldwide Research and Development from December 2010 until December 2018. Dolsten Mikael. Mikael Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics and vaccines. Dolsten Mikael. Pfizer also will start testing its rheumatoid-arthritis drug Xeljanz on coronavirus patients in Italy to see if it will help with the COVID-19 respiratory illness caused by the coronavirus. Dr. Dolsten is widely recognized as a leader within the medical research and drug development community. There is Mikael Dolsten, the Swedish Jewish head scientist at Pfizer, ... Israeli is jailed in Russia for alleged ties to Putin opposition group and not reporting foreign nationality The estimated Net Worth of Mikael Dolsten is at least $43.7 Million dollars as of 18 May 2020. The company was incorporated in Florida, Texas, California, and Nevada thirty-nine years ago. Mikael Dolsten, the Jewish Immigrant Leading Pfizer’s Vaccine Charge, Hopes the US Stays a Melting Pot. SEC Form 4 FORM 4: UNITED … With the departure of Mackay to AstraZeneca, Dolsten is expanding the role of Rod MacKenzie, who is currently senior vice president and head of worldwide research at Pfizer PharmaTherapeutics Research & Development. Former Wyeth executive takes charge of Pfizer Worldwide Research & Development. “Combatting the COVID-19 pandemic will require unprecedented collaboration across the innovation ecosystem, with companies coming together to unite capabilities like never before,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. Insider Trading Report. In addition to his current responsibilities leading small molecule research, MacKenzie will take charge of r&d strategy in Asia, as well as small molecules pharmaceutical science. He is a member of the Pfizer Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. Get up to date with the latest news and stories about the person Mikael Dolsten at The Irish Times. Senior Vice President President of Worldwide Research … Mikael Dolsten owns over 95,353 units of Pfizer stock worth over $6,025,925 and over the last 9 years he sold PFE stock worth over $28,025,243. AMRI manufactures lipid excipients for Pfizer-BioNTech COVID-19 vaccine, AMRI provides excipient manufacturing services for Pfizer-BioNTech, Auction: packaging equipment of vaccines and injectables from Pfizer, Pfizer to conduct first ‘virtual’ clinical trial in US, Pfizer signs clinical development agreements with Parexel and Icon, Pfizer expands alliance with Santaris Pharma, Pfizer ends cancer vaccine agreement with Celldex, Pfizer to purchase FoldRx Pharmaceuticals, Sigma-Aldrich to sell small molecule compounds from Pfizer. Insider Trading Report. Mikael Dolsten This page shows the track record and history of Dolsten Mikael insider trades in Karyopharm Therapeutics Inc.. Keynote remarks by Mikael Dolsten, M.D., Ph.D., President of Worldwide Research & Development, Pfizer Dr. Dolsten also previously held research leadership positions at AstraZeneca, Pharmacia and Upjohn. As Chief Scientific Officer, President, Worldwide Research, Development and Medical at PFIZER INC, M. Dolsten made $8,610,802 in total compensation. In addition, he makes $9,598,040 as Chief Scientific Officer, President - Worldwide Research et Development and Medical at Pfizer. Mikael’s scientific expertise, vision for R&D and commercial mindset have distinguished him at Pfizer and uniquely qualify him to lead our R&D colleagues and advance our pipeline. 2013 pay package: $6.5 million. About Form 4. doc4.html Zoom In Zoom Out > SEC FORM 4. Prior to his appointment at Wyeth, Dolsten held key r&d positions at Boehringer Ingelheim and AstraZeneca. “I feel confident that we will win, battle by battle, to turn around this viral war against our society,” Pfizer research-and-development chief Dr. Mikael Dolsten told The Wall Street Journal. Mikael Dolsten, president of worldwide research and development of Pfizer Inc., arrives at Portcullis House to give evidence to Parliament's Business, Science and Technology Select Committee in... Get premium, high resolution news photos at Getty Images from the University of Lund in Sweden, Mikael Dolsten was senior vice president of Wyeth and president … 2014 compensation: $1.2 million in salary; $1.9 million in … Speaking to a full room, Dr. Dolsten … Mikael Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics and vaccines. Former Wyeth executive takes charge of Pfizer Worldwide Research & Development. SINE Technology (Selective Inhibitor of Nuclear Export), Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274). From 2008 to 2009, Dr. Dolsten served as Senior Vice President of Wyeth, that was acquired by Pfizer in 2009, and President of Wyeth Research from 2008 to 2009. Change: +12.3%. That’s because Zaks, who earned a doctorate at Ben-Gurion University in Beersheba, is the chief medical officer […] About Form 4. doc4.html Zoom In Zoom Out > SEC FORM 4. Form 4 (Reporting) Published: 2019-03-05 16:54:58 Submitted: 2019-03-05 Filing Agent: CT's hCue Period Ending In: 2019-03-01. Dr. Dolsten has served as a member of our Board of Directors since March 2015. Pfizer Fined Again for Violating Drug Laws. The estimated Net Worth of Mikael Dolsten is at least $43.7 Milión dollars as of 18 May 2020. With a Ph.D. in tumor immunology and M.D. Mikael Dolsten, Pfizer. Mikael Dolsten owns over 95,353 units of Pfizer stock worth over $6,076,651 and over the last 9 years he sold PFE stock worth over $28,025,243. We are glad to share our knowledge with everyone,” Hermon added. Mikael Dolsten has become the sole executive in charge of r&d at Pfizer following the departure of Martin Mackay to AstraZeneca. Mikael Dolsten is Chief Scientific Ofcr/Pres:Worldwide Research & Dev at Pfizer Inc. See Mikael Dolsten's compensation, career history, education, & memberships. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. 2014 pay package: $7.3 million. In addition, he makes $9,598,040 as Chief Scientific Officer, President - Worldwide Research, and Development and Medical at Pfizer. Mikael Dolsten has become the sole executive in charge of r&d at Pfizer following the departure of Martin Mackay to AstraZeneca. The newly formed Pfizer Worldwide Research & Development organisation will include biotherapeutics, focused on large molecules and biotechnologies; pharmatherapeutics, which will concentrate on small molecules; and vaccines development. Mikael Dolsten to lead r&d at Pfizer. Dolsten has now become president of Pfizer Worldwide Research & Development and Mackay has taken the newly created position of president of r&d at AstraZeneca. Join Facebook to connect with Mikael Dolsten and others you may know. Mikael Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics and vaccines. Dr. Dolsten has served as President of Worldwide Research, Development and Medical, Chief Scientific Officer and Executive Vice President of Pfizer Inc., one of the largest public pharmaceutical companies in the world, since 2010. Biography of Mikael Dolsten Currently, Mikael Dolsten holds the position of Chief Scientific Officer at Pfizer Inc. The estimated Net Worth of Mikael Dolsten is at least $43.6 million dollars as of 18 May 2020. Background Report for Mikael Dolsten. He is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. He is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. Currently, Mikael Dolsten holds the position of Chief Scientific Officer at Pfizer Inc. Mikael Dolsten owns over 95,353 units of Pfizer stock worth over $6,076,651 and over the last 9 years he sold PFE stock worth over $28,025,243. The firm will now implement a diversified r&d platform with the same breadth and research programmes under Dolsten’s leadership. He is a member of the Pfizer Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities. Dr. Mikael Dolsten, M.D., Ph.D., is the President Worldwide Research and Development of the Company. Of this total $1,400,000 was received as a salary, $1,820,000 was received as a bonus, $2,531,376 was received in stock options, $2,414,725 was awarded as stock and $444,701 came from other types of compensation. by Marco Cáceres on September 8, 2019. Pfizer said it initially implemented this two-division structure (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both organisations. A New Survey Could Tell You ... nationality or any other consideration. Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. “Mikael Dolsten is an exceptional scientist who is highly regarded and committed to bringing new preventative measures, treatments and cures to people. Mikael Dolsten is focused on advancing the company’s scientific leadership in small molecule medicines, biotherapeutics and vaccines. Dolsten will now lead all of research at Pfizer, as well as development of all compounds through Phase 2, or ‘proof of concept.’ Late-stage clinical development will continue to be led by clinical teams throughout the Worldwide Biopharmaceutical Businesses. Breaking News at IrishTimes.com.